PATIENT CASES

Have You Considered Prescribing OPSYNVI® for Your Patients With PAH?

Click on a patient to explore their clinical history.

*Appropriate hypothetical patient.

"It simplifies things, it simplifies my treatment regimen, and it's convenient for me to take 1 pill, once a day." –OPSYNVI® Patient

OPSYNVI® (macitentan/tadalafil) is priced the same as OPSUMIT® (macitentan)6†‡

  • Patients avoid the added cost of a separate PDE5i prescription6
  • PDE5i co-pays can range from $15 to $150/month before deductibles7

Choose OPSYNVI® today

†

OPSYNVI® and OPSUMIT® have identical list prices as of January 2026.6

‡

When both drugs are covered on the same formulary tier by the patient's insurance.

6MWD=6-minute walk distance; BNP=brain natriuretic peptide; ERA=endothelin receptor antagonist; FC=Functional Class; NT-proBNP=N-terminal pro-brain natriuretic peptide; PAH=pulmonary arterial hypertension; PDE5i=phosphodiesterase type 5 inhibitor; PVR=pulmonary vascular resistance.

References: 1. OPSYNVI® (macitentan/tadalafil) full Prescribing Information. Actelion Pharmaceuticals US, Inc. 2. Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2022;43(38):3618-3731. 3. Pulido T, Adzerikho I, Channick RN, et al; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809-818 and suppl 1-21. doi:10.1056/NEJMoal213917 4.  REVATIO® Prescribing Information. Pfizer. 5.  ADCIRCA® Prescribing Information. Eli Lily & Co. 6. Data on file. Johnson & Johnson and its affiliates. Master Price List. Accessed January 2, 2026. 7.  Data on file. Johnson & Johnson and its affiliates. Potential OOP for PDE5i. May 7, 2025.